A first-of-its-kind clinical trial has launched in the UK, which could cut years from the search for treatments that work for people with Alzheimer’s disease. 

The national trial, called AD-SMART (Alzheimer’s disease Systematic Multi-arm Adaptive Randomised Trial), is led by the UK Dementia Research Institute (UK DRI) and Alzheimer’s Research UK (ARUK) – in partnership with the National Institute for Health and Care Research (NIHR), the Medical Research Council (MRC) and Health Data Research UK (HDR UK), with ongoing funding committed by UK government to support the trial. 

It will test multiple drugs simultaneously, starting with two repurposed medicines already used to treat type 2 diabetes and attention deficit hyperactivity disorder (ADHD). Groups of participants will each begin treatment with a different drug.  

The study will examine whether these medicines can lessen symptoms such as memory and thinking problems, and help people maintain their quality-of-life as the disease progresses. 

As well as repurposed drugs, the trial is designed to test new potential treatments coming through the research pipeline. 

The UK Prime Minister said: “I know how it feels to lose a loved one to dementia and have seen first-hand the devastating impact this illness has on families. That’s why I’m proud to see this trial being launched in the UK, so that cutting edge treatments can reach patients here as soon as possible. I have made dementia research a national priority. I want Britain to be the leading nation, making the breakthroughs that change people’s lives.” 

Testing several drugs against one shared placebo group means that ̶̶̶compared with a traditional trial, the time to evaluate treatments can be more than halved, which also reduces costs. 

AD-SMART to recruit 1,200 participants 

The trial is being delivered by a team at Imperial College London, the UCL Innovative Clinical Trials Unit and the MRC Centre of Research Excellence in Clinical Trial Innovation (UCL), the University of Oxford and Dementias Platform UK (DPUK), with support from leading Alzheimer’s experts from across the UK. 

Chief Investigator, Professor Paresh Malhotra, Group Leader at the UK Dementia Research Institute (UK DRI) Centre for Care Research & Technology at Imperial College London, said: “For too long, Alzheimer’s research has moved at the pace of one drug, one trial, one answer, sometimes taking a decade or more before we know if we’ve found something that works. We are applying advances from cancer and other conditions to accelerate testing of treatments for people with Alzheimer’s disease. The way AD-SMART is set up means we’re testing several treatments at the same time, and those that don’t show promise can be quickly stopped. Then we can start testing something else. That’s the best way to get effective treatments to patients as quickly as we can.” 

Up to 20 NHS sites are expected to open across the UK over the next 12-18 months and more than 30 are planned overall. Researchers aim to recruit 1,200 participants across the UK to test these first two drugs. They expect to finish evaluating the first drugs in 2030, in around four years’ time. During this initial four-year period, the team expect additional drugs to be added into the trial for testing. 

The model has already proven itself in the UK. MND-SMART, a similar platform trial for motor neuron disease, also led by the UK DRI, concluded that its first drugs tested were ineffective in just over three years – a process that would normally take at least eight. The trial has now moved on to testing other promising drugs.